Carbonic acid bis-benzyloxy-phosphoryloxymethyl ester 4-chloro-2-[2-oxo-5-(4-trifluoromethyl-phenyl)-[1,3,4]oxadiazol-3-ylmethyl]-phenyl ester | 233676-42-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: Carbonic acid bis-benzyloxy-phosphoryloxymethyl ester 4-chloro-2-[2-oxo-5-(4-trifluoromethyl-phenyl)-[1,3,4]oxadiazol-3-ylmethyl]-phenyl ester
• CAS: 233676-42-1
• 化学式: C₃₂H₂₅ClF₃N₂O₉P
• 分子量: 704.98
• InChiKey: HQVXBMGYTOHFLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.26
• 重原子数：
  48.0
• 可旋转键数：
  13.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  128.32
• 氢给体数：
  0.0
• 氢受体数：
  11.0

反应信息

• 作为反应物：
  描述：

  Carbonic acid bis-benzyloxy-phosphoryloxymethyl ester 4-chloro-2-[2-oxo-5-(4-trifluoromethyl-phenyl)-[1,3,4]oxadiazol-3-ylmethyl]-phenyl ester 在 platinum(IV) oxide 氢气 作用下， 以 乙酸乙酯 为溶剂， 生成 3-[(5-Chloro-2-[[[(phosphonooxy)methyl]oxy]carbonyloxy]-phenyl)methyl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one
  参考文献：
  名称：

  Synthesis of water-Soluble prodrugs of BMS-191011: A maxi-K channel opener targeted for post-stroke neuroprotection

  摘要：

  A variety of water-soluble prodrugs of BMS-191011 was synthesized and evaluated for solution state stability and rate of conversion to BMS-191011 in rat and human plasma. The deoxycarnitine ester prodrug (11c) was selected for clinical evaluation based on its superior chemical stability, crystallinity and cleavage to BMS-191011 in human plasma. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00296-8
• 作为产物：
  描述：

  3-(5-氯-2-羟基苄基)-5-(4-(三氟甲基)苯基)-1,3,4-噁二唑-2(3h)-酮 在 吡啶 、 sodium iodide 作用下， 以 二氯甲烷 、 丙酮 、 苯 为溶剂， 生成 Carbonic acid bis-benzyloxy-phosphoryloxymethyl ester 4-chloro-2-[2-oxo-5-(4-trifluoromethyl-phenyl)-[1,3,4]oxadiazol-3-ylmethyl]-phenyl ester
  参考文献：
  名称：

  Synthesis of water-Soluble prodrugs of BMS-191011: A maxi-K channel opener targeted for post-stroke neuroprotection

  摘要：

  A variety of water-soluble prodrugs of BMS-191011 was synthesized and evaluated for solution state stability and rate of conversion to BMS-191011 in rat and human plasma. The deoxycarnitine ester prodrug (11c) was selected for clinical evaluation based on its superior chemical stability, crystallinity and cleavage to BMS-191011 in human plasma. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00296-8